Signal transduction in anaplastic large cell lymphoma cells (ALCL) mediated by the tumor necrosis factor receptor CD30

Leuk Lymphoma. 2004 May;45(5):1009-15. doi: 10.1080/1042819031000149322.

Abstract

Expression of the cytokine receptor CD30 is a characteristic feature of anaplastic large cell lymphoma (ALCL). Reports regarding CD30-mediated signaling in ALCL cells are highly controversial, especially with respect to the regulation of cell survival. In this study, we stimulated 6 ALCL-derived cell lines with immobilized anti-CD30 antibody. CD30-induced cell death was investigated by Western blot and FACS analysis. CD30-dependent cell proliferation and activation was analyzed by applying the trypan blue exclusion method and a luciferase-based ATP assay. The expression of cell cycle relevant proteins and the activation of mitogen-activated protein (MAP) kinases were also examined. We demonstrated that activation of CD30 did not lead to the cleavage of pro-caspase-3. FACS analysis confirmed that in all examined cells cell death was not mediated by CD30. Cell growth was strongly inhibited in 2 of the 6 cell lines and restrained cell growth was accompanied by expression of the cell cycle inhibitor p21(WAF1/CIP1). Furthermore, stimulation of CD30 led to the activation of the p38 MAP kinase but not of the extracellular signal-regulated kinase (ERK) or the jun N-terminal kinase (JNK). Interestingly, activation of CD30 induced a strong synergistic reduction of cell activity, if the p38 MAP kinase activity was blocked by SB203580. The aim of the study was to elucidate CD30-induced signaling in different ALCL-cells. Our results suggest that CD30-mediated apoptosis is not a common feature in this cell type and that p38 MAP kinase is involved in CD30-mediated singal transduction.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / pharmacology
  • Apoptosis / drug effects
  • Cell Cycle Proteins / genetics
  • Cell Proliferation / drug effects
  • Cyclin-Dependent Kinase Inhibitor p21
  • Gene Expression Regulation / drug effects
  • Humans
  • Ki-1 Antigen / immunology
  • Ki-1 Antigen / physiology*
  • Lymphoma, Large-Cell, Anaplastic / pathology*
  • Mitogen-Activated Protein Kinases / metabolism
  • Signal Transduction*
  • p38 Mitogen-Activated Protein Kinases / metabolism

Substances

  • Antibodies, Monoclonal
  • CDKN1A protein, human
  • Cell Cycle Proteins
  • Cyclin-Dependent Kinase Inhibitor p21
  • Ki-1 Antigen
  • Mitogen-Activated Protein Kinases
  • p38 Mitogen-Activated Protein Kinases